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Background: There is little information about the effect of infliximab on the clinical course of liver disease
in Crohn’s disease patients with concomitant hepatitis B virus (HBV) infection. Theoretically,
immunosuppression induced by infliximab will facilitate viral replication which could be followed by a
flare or exacerbation of disease when therapy is discontinued. There are no specific recommendations on
surveillance and treatment of HBV before infliximab infusion. Two cases of severe hepatic failure related to
infliximab infusions have been described in patients with rheumatic diseases.
Patients and methods: Hepatitis markers (C and B) and liver function tests were prospectively determined
to 80 Crohn’s disease patients requiring infliximab infusion in three hospitals in Spain.
Results: Three Crohn’s disease patients with chronic HBV infection were identified. Two of the three
patients with chronic HBV infection suffered severe reactivation of chronic hepatitis B after withdrawal of
infliximab therapy and one died. A third patient, who was treated with lamivudine at the time of infliximab
therapy, had no clinical or biochemical worsening of liver disease during or after therapy. From the
remaining 80 patients, six received the hepatitis B vaccine. Three patients had antibodies to both hepatitis
B surface antigen (anti-HBs) and hepatitis B core protein (anti-HBc) with normal aminotransferase levels,
and one patient had positive anti-hepatitis C virus (HCV) antibodies, negative HCV RNA, and normal
aminotransferase levels. Except for the patients with chronic HBV infection, no significant changes in
hepatic function were detected.
Conclusions: Patients with Crohn’s disease who are candidates for infliximab therapy should be tested for
hepatitis B serological markers before treatment and considered for prophylaxis of reactivation using
antiviral therapy if positive.
I
nfliximab is the treatment of choice for patients with
moderately to severely active and fistulising Crohn’s
disease (CD) which is unresponsive to conventional
treatment. Its use is contraindicated in the presence of active
infection. However, recommendations with respect to pre-
vention and treatment of infection before infliximab infusion
mainly refer to bacterial and opportunistic infections.1 There
is scarce information about the effect of immunomodulatory
drugs on the clinical course of liver disease in CD patients
with concomitant hepatitis B virus (HBV) or hepatitis C virus
(HCV) infection.2 3 To date, the available information
suggested that HCV and HBV infection should not influence
treatment strategies for CD.2–5 However, two cases of severe6
or fulminant B hepatitis7 related to infliximab therapy have
been reported in patients with rheumatic diseases. More
recently, a patient with chronic hepatitis B receiving
lamivudine therapy requiring infliximab for ankylosing
spondylitis showed no significant change in liver disease or
viral replication.8
We report three CD patients and concomitant chronic
hepatitis B from a cohort of 80 CD patients treated with
infliximab in three different hospitals in Spain. Two patients
showed hepatitis B reactivation, with resolution of infection
in one case and a fatal outcome in the other. The third
patient, simultaneously treated with lamivudine, showed no
clinical or biochemical effects on liver disease.
PATIENTS AND METHODS
From January 2000 to July 2003, 80 CD patients (45 men, 35
women; mean age 38.2 years (range14–80)) were treated
with infliximab in three different hospitals in Spain. The
number of infusions per patient ranged from 1 to 22.
Hepatitis C and B markers were prospectively determined
before the first infliximab infusion in two hospitals as part of
the baseline assessment prior to infliximab treatment. In the
third hospital, serum was prospectively obtained before every
infliximab infusion and stored in the serum bank. Hepatitis C
and B markers of all patients treated in this hospital were
analysed in basal sera. Markers for HBV and HCV were
identified using the following techniques: hepatitis B surface
antigen (HBsAg), antibodies to hepatitis B surface antigen
(anti-HBs), antibodies to hepatitis B core protein (anti-HBc),
hepatitis B e antigen (HBeAg), antibodies to hepatitis B e
antigen (anti-HBe), and anti-HCV were detected by the
Roche (Roche Diagnostics, Basel, Switzerland) EIA method
(Cobas Core II System), HCV RNA by the Roche PCR process
(Cobas Amplicor HCV Monitor Test, v 2.0), and HBV DNA by
Diagene’s (Gaithesburg, Maryland, USA) Hybrid Capture II
assay. Liver function tests were prospectively determined in
the three hospitals before every infliximab infusion and two
months after the last infusion. Aminotransferase levels
(alanine aminotransferase (ALT), aspartate aminotransferase
(AST)), alkaline phosphatase, gamma glutamyl transferase
(GGT), and total bilirubin were measured by standard
laboratory methods.
RESULTS
Three of 80 patients had chronic hepatitis B at the time of
infliximab infusion, one with active viral replication. The case
Abbreviations: CD, Crohn’s disease, HBV, hepatitis B virus; HCV,
hepatitis C virus; anti-HBs, antibodies to hepatitis B surface antigen; anti-
HBc, antibodies to hepatitis B core protein; HBsAg, hepatitis B surface
antigen; HBeAg, hepatitis B e antigen; anti-HBe, antibodies to hepatitis B
e antigen; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; GGT, gamma glutamyl transferase
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reports of these three patients are described below in detail.
Six more patients received the hepatitis B vaccine several
months before infliximab treatment and anti-HBs levels
higher than 100 mIU/ml were detected before the first
infusion. Three patients showed positivity for both anti-HBs
and anti-HBc with normal aminotransferase levels, suggest-
ing spontaneous resolution of infection months or years
before infliximab treatment. One patient had positive anti-
HCV antibodies, negative HCV RNA, and normal amino-
transferase levels. Except for patients with chronic hepatitis B
infection, no significant changes in hepatic function were
detected during infliximab therapy.
Case No 1
A 34 year old man was diagnosed with CD of the ileocaecal
and sigmoid area in August 2000. He was treated with
prednisone 70 mg/day and enteral nutrition, developing
steroid dependence in the following six months. Mild
hypertransaminasaemia was recorded and attributed to
enteral nutrition. He was given azathioprine 2.5 mg/kg/day
in February 2001, and in May 2001 he developed a fistulous
tract from the terminal ileum to the urinary bladder.
Ciprofloxacin was added as maintenance treatment to avoid
urinary sepsis, and infliximab was administered at a dose of
5 mg/kg with an induction regimen of three doses. Partial
remission was observed but early relapse occurred and
surgical resection of the intestinal segment was indicated.
An additional infusion of infliximab 10 days before sur-
gery was administered in order to reduce inflammation.
Resection of 40 cm of the terminal ileum and of three
fistulous ileovesical tracts was performed. Two months
later the patient experienced malaise and nausea. Blood
analysis disclosed increased levels of serum ALT (2089 IU/l),
AST (1561 IU/l), alkaline phosphatase (540 IU/l), gamma
glutamyl transferase (GGT 165 IU/l ), and total bilirubin
(1.7 mg/dl). Mild hypoalbuminaemia (32 g/l) and a decrease
in prothrombin rate (75%) were also found and the patient
was admitted to hospital. Abdominal ultrasonography
was normal. Serum markers for hepatitis A virus, HCV,
cytomegalovirus, Epstein-Barr virus, and herpes virus were
negative. IgM anti-HBc antibodies and high serum HBV/DNA
polymerase levels were detected (10 400 pg/ml). Archival
serum, obtained previous to the first infliximab infusion, was
recovered and serological markers of B and delta agents were
determined. Positive HBsAg, IgG anti-HBc, HBeAg, and HBV/
DNA, and negative anti-HBs, IgM anti-HBc, anti-HBe, as well
as IgM and IgG anti-delta were detected. Thus acute hepatitis
caused by HBV reactivation was diagnosed.
The clinical outcome was excellent and three months later
serum AST and ALT levels returned to normal and
seroconversion from HBeAg to anti-HBe was documented,
HBsAg was cleared, and HBV/DNA was undetectable.
Case No 2
A 38 year old man was diagnosed with ileocaecal CD with
severe fistulising disease in 1979. He required multiple
surgical procedures, including ileal and segmental colonic
resections, and he received repeated transfusions. In 1987,
persistent elevation of ALT and AST were detected and
chronic hepatitis B was diagnosed. In 1990, the patient
developed jaundice and coluria, and acute exacerbation of
hepatitis, and a sharp increase in ALT (1030 IU/l), AST
(1100 IU/l), and GGT (255 IU/l) was detected. HBV markers
showed positive HBsAg, IgM anti-HBc, and HBeAg, confirm-
ing reactivation of HBV. Delta and C viruses were negative.
One month later, ALT and AST levels returned to normal and
seroconversion from HBeAg to anti-HBe with persistent
HBsAg was documented. No immunosuppressive drugs had
been administered in the previous six months.
From 1993 to 2000, the patient was receiving azathioprine
and metronidazole, maintaining perianal fistulous tracks
with variable drainage. Liver function tests were not
influenced by immunosuppression. In 2000, in spite of
azathioprine therapy, perianal disease worsened with the
appearance of multiple fistulous tracks arising in a strictured
and inflamed anorectal area. Infliximab therapy with a three
dose induction regimen was indicated and azathioprine was
maintained. Hepatitis virus infection was previously assessed
showing positive HBsAg, IgG anti-HBc, and anti-HBe, and
negative HBeAg and HBV/DNA. Delta and C viruses were
negative. Partial remission with decreased drainage and
normalisation of laboratory parameters of inflammation
occurred.
Three months after the last infliximab dose, the patient
developed jaundice and coluria, malaise, and weight loss.
Physical examination revealed mucocutaneous jaundice
and reappearance of severe perianal disease. Blood analysis
showed increased levels of ALT (2225 IU/l), AST (2146 IU/l),
GGT (227 U/l ), total bilirubin (24.1 mg/dl), decrease in
prothrombin rate (50%), and elevation of serum a-feto-
protein levels (589 ng/ml). The liver appeared normal on
ultrasonography and there was no ascites. Serum markers
of hepatitis A and C, cytomegalovirus, Epstein-Barr virus,
and herpes virus were negative. Positive IgM anti-HBc
antibodies, HBeAg, and high serum HBV/DNA polymerase
levels were detected (9000 pg/ml). After initial improve-
ment, the patient developed subacute hepatic failure with
ascites, marked hyperbilirubinaemia (29.8 mg/dl), and hypo-
prothrombinaemia (27%). The patient died of variceal bleed-
ing, encephalopathy, and hepatorenal syndrome before he
could undergo liver transplantation.
Case No 3
A 26 year old man was diagnosed with CD in 1995 due to
perianal abscess and fistulas, and was shown to have
extensive colitis with ileal and rectal sparing. He was initially
managed with metronidazole and mesalazine with an
acceptable response. Blood analysis at diagnosis showed
normal liver function values. In June 1999, increased levels of
ALT (67 IU/l) and AST (36 IU/l) were found, which persisted
in subsequent controls. HBsAg, IgG anti-HBc, HBeAg, and
HBV DNA were positive, and anti-HBs, anti-HBe, and IgM
anti-HBc were negative. Other causes of liver damage such as
HCV and delta viruses were ruled out and liver biopsy,
performed in February 2000, confirmed a diagnosis of chronic
hepatitis with mild portal and lobular activity without
fibrosis. Lamivudine 100 mg daily was started two months
later showing a good response with HBeAg seroconversion,
HBV/DNA clearance, aminotransferase normalisation, and
positive HBsAg, which still persists.
In November 2001, the patient experienced a relapse of CD
with severe perianal disease and was treated with azathio-
prine 2.5 mg/kg/day. In July 2003, infliximab was added to
the treatment—due to recurrence of perianal disease with
repeated abscess formation—after abscess drainage and
seton placement. Three doses of infliximab were adminis-
tered followed by eight weeks of maintenance treatment (two
additional doses), resulting in a complete and sustained
response. Lamivudine was also maintained and no flare up of
HBV infection was detected in blood analysis performed
every two months.
DISCUSSION
A frequency of HBV and HCV as high as 24% has been
reported in patients with CD, generally related to surgical
procedures and blood transfusions.2 In our series of 80
patients treated with infliximab, a much lower prevalence
rate than previously described was found (7.5% and 1.2% for
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HBV and HCV, respectively). Immunosuppressive drugs in
chronically infected patients may lead to enhanced viral
replication with exacerbation of hepatitis. Hepatitis rebound
generally occurs after immunosuppression withdrawal and
the magnitude of the hepatocellular response theoretically
depends on the potency of the immunosuppressors.9
However, in spite of a potentially harmful effect of infliximab
therapy on the course of viral hepatitis, there is little
information about the influence of this treatment in the
course of coexistent viral hepatitis in CD patients. In
addition, there are no specific recommendations for viral
hepatitis surveillance in this setting.
Our first two cases showed typical signs of HBV infection
in patients receiving immunosuppressive therapy.9 10 Acute
flare of hepatitis occurred 2–3 months after infliximab
withdrawal. In the first case, recovery to a normal immune
response produced HBV clearance and HBeAg seroconver-
sion. In contrast, in the second case, extensive cytolysis
occurred that led to hepatic failure and death. Lamivudine, a
reverse transcriptase inhibitor, has been used with success in
the treatment of chemotherapy related HBV reactivation
in patients with haemato-oncological neoplasms11 and in
transplant recipients,12 13 and it could be a therapeutic option
in these patients. However, severe flare up, as was the case in
patient No 2, with high levels of bilirubin at presentation,
seem to be predictors of treatment failure.13 A similar scenario
was described in two rheumatic patients treated with
infliximab.6 7 In one case clear reactivation of HBV hepatitis
was documented6; in the other, who required liver trans-
plantation, no evidence of either serological or histological
reactivation of HBV was demonstrated.7 Both patients were
treated with lamivudine and showed normalisation of liver
function tests and persistence of HBsAg.
In No case 3, lamivudine was effective in inducing HBeAg
seroconversion and was useful as primary prophylaxis of HBV
reactivation when infliximab was added to azathioprine
therapy. Such a preventive effect has also been demonstrated
in a patient with chronic hepatitis B and ankylosing
spondylitis requiring infliximab therapy.8 In addition, lami-
vudine, as primary prophylaxis for HBV reactivation, has
been used with success in a small series of patients treated
with potent immunosuppressors12 and more recently in a case
control study performed in patients with allogenic haemato-
poietic stem cell transplantation.14 Unfortunately, data on the
long term benefits of lamivudine are limited and mutations
in the polymerase gene may emerge as soon as 6–9 months
after therapy, inducing lamivudine resistance.10 15 In lamivu-
dine resistant HBV mutants, adefovir dipivoxil is a ther-
apeutic option and should be taken into account when long
term infliximab therapy is foreseen.16
Three additional patients in the present series had posi-
tive antibodies to HBV, suggesting past infection. Amino-
transferase levels in these patients remained within the
normal range before and after infliximab therapy. However, it
is important to note that reactivation can also occur in anti-
HBc positive HBsAg negative patients because HBV may
persists even after serological recovery.16 17 Thus infliximab
should be administered with caution in these patients and
liver function tests should be closely monitored.
In conclusion, our finding of reactivation of hepatitis B in
HBsAg positive patients emphasises the need for careful
monitoring of viral hepatitis infection in patients with
inflammatory bowel disease requiring immunosuppressive
therapy, particularly infliximab. Antiviral therapy (lamivu-
dine or adefovir dipivoxil) should be administered to those
patients requiring infliximab therapy who exhibit positive
surface antigen (HBsAg) with or without active viral
replication. In addition, hepatitis B vaccination should be
routinely recommended in all CD patients at diagnosis.
ACKNOWLEDGEMENTS
The authors are grateful to Fernando Ferna´ndez-Ban˜ares, MD, and
Eduard Cabre´, MD, for their valuable suggestions.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
M Esteve, M Forne´, J M Viver, Department of Gastroenterology,
Hospital Universitari Mu´tua de Terrassa, Terrassa, Catalonia, Spain
C Saro, Department of Internal Medicine, Hospital de Cabuen˜es, Gijo´n,
Asturias, Spain
F Gonza´lez-Huix, Department of Gastroenterology, Hospital Josep
Trueta, Girona, Catalonia, Spain
F Suarez, Department of Gastroenterology, Hospital Juan Canalejo, La
Corun˜a, Spain
REFERENCES
1 Schreiber S, Campieri M, Colombel JF, et al. Use of anti-tumour necrosis
factor agents in inflammatory bowel disease. European guidelines for 2001–
2003. Int J Colorectal Dis 2001;16:1–13.
2 Biancone L, Pavia M, Del Vecchio Blanco G, et al. Hepatitis B and C virus
infection in Crohn’s disease. Inflamm Bowel Dis 2001;7:287–94.
3 Biancone L, Del Vecchio Blanco G, Pallone F, et al. Immunomodulatory drugs
in Crohn’s disease patients with hepatitis B or C virus infection.
Gastroenterology 2002;122:593.
4 Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn’s
disease and concomitant chronic hepatitis C with a chimeric monoclonal
antibody to TNF. Am J Gastroenterol 2003;98:504–5.
5 Campbell S, Ghosh S. Infliximab therapy for Crohn’s disease in the presence
of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001;13:191–2.
6 Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis
B surface antigen carrier with rheumatoid arthritis treated with infliximab and
low dose methotrexate. Ann Rheum Dis 2003;62:686–7.
7 Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a
patient with hepatitis B virus treated for an adult onset Still’s disease.
J Rheumatol 2003;30:1624–5.
8 Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic
diseases in patients with chronic hepatitis B or C. J Rheumatol
2004;31:107–9.
9 Perrillo RP. Acute flares in chronic hepatitis B: The natural and unnnatural
history of an immunologically mediated liver disease. Gastroenterology
2001;120:1009–22.
10 Liaw Y-F. Hepatitis flares and hepatitis B e antigen seroconversion: Implication
in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003;18:246–52.
11 Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in
chronic HBsAg carriers with hemato-oncological neoplasias with
chemotherapy. Leuk Lymphoma 2003;44:759–66.
12 Lee WC, Wu MJ, Cheng CH, et al. Lamivudine is effective for the treatment of
reactivation of hepatitis B virus and fulminant hepatic failure in renal
transplant recipients. Am J Kidney Dis 2001;38:1074–81.
13 Liu CJ, Lai MY, Lee PH, et al. Lamivudine treatment for hepatitis B reactivation
in HBsAg carriers after organ transplantation: a 4-year experience.
J Gastroenterol Hepatol 2001;16:1001–8.
14 Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis
B exacerbation after allogeneic hematopoietic cell transplantation.
Hepatology 2002;36:702–9.
15 Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol
2003;38(suppl 1):S90–103.
16 Tillmann HL, Wedemeyer H, Manns MP. Treatment of hepatitis B in special
patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis,
hepatitis B reactivation. J Hepatol 2003;39:S206–11.
17 Marusawa H, Uemoto S, Hijikata M, et al. Latent hepatitis B virus infection in
healthy individuals with antibodies to hepatitis B core antigen. Hepatology
2000;31:488–95.
HBV hepatitis and infliximab 1365
www.gutjnl.com
 group.bmj.com on March 31, 2011 - Published by gut.bmj.comDownloaded from 
doi: 10.1136/gut.2004.040675
 2004 53: 1363-1365Gut
 
M Esteve, C Saro, F González-Huix, et al.
 
need for primary prophylaxis
patients:infliximab therapy in Crohn's disease 
Chronic hepatitis B reactivation following
 http://gut.bmj.com/content/53/9/1363.full.html
Updated information and services can be found at: 
These include:
References
 http://gut.bmj.com/content/53/9/1363.full.html#related-urls
Article cited in: 
 
 http://gut.bmj.com/content/53/9/1363.full.html#ref-list-1
This article cites 15 articles, 3 of which can be accessed free at:
service
Email alerting
box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic
 (58 articles)Hepatitis B   
 
Articles on similar topics can be found in the following collections
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on March 31, 2011 - Published by gut.bmj.comDownloaded from 
